Join
Live feed
·
PRReleasevia Quantisnow
InflaRx N.V. logo

InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

ByQuantisnow·Wall Street's wire, on your screen.
IFRX· InflaRx N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IFRX (InflaRx N.V.) and more on Quantisnow.